medigraphic.com
Colegio de Medicina Interna de México.

2020, Número S1

<< Anterior

Med Int Mex 2020; 36 (S1)


Sintomas depressivos e o tratamento da esquizofrenia

De Alencar Araripe-Neto AG, Bessa-Diniz EJ

Idioma: Portugués
Referencias bibliográficas: 26
Paginas: 32-35
Archivo PDF: 289.23 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lieberman JA. Neurobiology and the natural history of schizophrenia. J Clin Psychiatry. 2006 Oct;67(10):e14.

  2. Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012 May;137(1-3):246-50.

  3. Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013 Sep;45(9):984-94.

  4. van Os J, Kapur S. Schizophrenia. (2009). Schizophrenia. Lancet. 2009 Aug 22;374(9690):635-45.

  5. Craig TJ, Richardson MA, Pass R, Bregman Z. Measurement of mood and affect in schizophrenic inpatients. Am J Psychiatry. 1985 Nov;142(11):1272-7.

  6. Siris SG. Depression in schizophrenia: Perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry. 2000;157(9):1379–89.

  7. Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009). Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009 Mar;35(2):383–402.

  8. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res. 1996 May;19(2-3):205-12.

  9. Bressan RA, Chaves AC, Shirakawa I, Mari JJ. Validity study of the Brazilian version of the Calgary Depression Scale for Schizophrenia. Schizophr Res. 1998;32:31–9.

  10. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015 Apr;16(3):142-70.

  11. Siris SG, Addington D, Azorin JM, Falloon IR, Gerlach J, Hirsch SR. Depression in schizophrenia: Recognition and management in the USA. Schizophr Res. 2001;47(2– 3):185–97.

  12. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007 Feb;90(1-3):186-97.

  13. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: Systematic review of risk factors. Br J Psychiatry. 2005 Jul;187:9-20.

  14. Mulholland C, Cooper S. The symptom of depression in schizophrenia and its management. Adv Psychiatr Treat. 2000;6(3):169–77.

  15. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in First-Episode. Am J Psychiatry. 1993;150:1643–8.

  16. Birchwood M, Mason R, MacMillan F, Healy J. Depression, demoralization and control over psychotic illness a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med. 1993 May;23(2):387-95.

  17. Leucht S, Heres S, Kissling W, Davis JM. Pharmacological Treatment of Schizophrenia. Fortschr Neurol Psychiatr. 2013 May;81(5):e1-13.

  18. Gregory A, Mallikarjun P, Upthegrove R. Treatment of depression in schizophrenia: systematic review and metaanalysis. Br J Psychiatry. 2017 Oct;211(4):198-204.

  19. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2002;(2):CD002305.

  20. Morrissette DA, Stahl S M. Affective symptoms in schizophrenia. Drug Discov Today Ther Strateg. 2011;8(1–2):3–9.

  21. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31-41.

  22. Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS. nTypical antipsychotic drugs — D2 receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res. 2002 Jul 1;56(1-2):31-6.

  23. Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al. Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia. J Clin Psychiatry. 2011 Jan;72(1):75-80.

  24. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97- 170.

  25. Rendell JM, Gijsman HJ, Keck PK, Goodwin G, Geddes J. Olanzapine alone or in combination for acute mania (Review). Cochrane Database Syst Rev. 2003;3:CD004040.

  26. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003 Jan;60(1):82-91.




2020     |     www.medigraphic.com